iPSC-CAR-T cell therapy

iPSC-CAR-T cell therapy is an advanced form of chimeric antigen receptor (CAR) T-cell immunotherapy in which T cells are generated from induced pluripotent stem cells (iPSCs) and genetically engineered to express a CAR targeting specific antigens on tumor or pathogenic cells. Unlike conventional autologous CAR-T therapies that use a patient’s own T cells, this approach enables the creation of an unlimited, uniform supply of allogeneic (“off-the-shelf”) therapeutic T cells. The process involves reprogramming donor somatic cells into iPSCs, differentiating them into functional T lymphocytes, and then engineering these with a CAR construct for targeted cytotoxicity. This technology offers several advantages over traditional methods including scalability, enhanced proliferative capacity and persistence, reduced risk of exhaustion markers (such as PD-1), and the potential for broader accessibility due to banking and standardized manufacturing[2][8][10]. The primary indications under investigation include hematologic malignancies (such as B-cell leukemias/lymphomas) and autoimmune diseases like systemic lupus erythematosus[6][9]. Fate Therapeutics is among the leading developers in this field with its FT819 product currently in Phase 1 clinical trials for lupus.

Other names

induced pluripotent stem cell-derived CAR T-cell therapyiPSC-derived CAR T-cell therapyiCAR-T